Table 1.
Patient demographic and prior treatment characteristics
| Characteristic | No. (%) or Median [range] |
|---|---|
| No. of patients | 23 |
| Age, years | 59 [40-85] |
| Male sex | 13 (56.5) |
| Karnofsky performance status ≥80% | 22 (95.6) |
| Initial tumor location | |
| Head of pancreas | 13 (56.5) |
| Body of pancreas | 7 (30.5) |
| Uncinate process | 2 (8.7) |
| Tail of pancreas | 1 (4.3) |
| Tumor histology | |
| Ductal adenocarcinoma | 21 (91.4) |
| Mucinous non-cystic carcinoma | 1 (4.3) |
| Adeno-squamous carcinoma | 1 (4.3) |
| Initial TNM staging | |
| Tumor (T) | |
| T1 | 2 (8.7) |
| T2 | 4 (17.3) |
| T3 | 7 (30.5) |
| T4 | 10 (43.5) |
| Node (N) | |
| N0 | 15 (65.2) |
| N1 | 8 (34.8) |
| Metastases (M) | |
| M0 | 23 (100) |
| M1 | 0 (0) |
| Initial resectable disease, yes | 12 (52.2) |
| Surgery characteristics | |
| Whipple procedure | 8 (66.7) |
| Distal pancreatectomy | 4 (33.3) |
| Vessel reconstruction, yes | 2 (16.7) |
| Negative margins, yes | 8 (66.7) |
| Perineural invasion, yes | 2 (16.7) |
| Lymphovascular invasion, yes | 2 (16.7) |
| Prior radiation therapy regimen (conventional fractionation) | |
| Neoadjuvant to surgery | 2 (8.7) |
| Adjuvant to surgery | 10 (43.5) |
| Definitive | 11 (47.8) |
| Total dose, Gy | 50.4 [30-60] |
| No. of fractions | 28 [10-30] |
| Prior chemotherapy regimen∗ | |
| Gemcitabine based | 22 (95.6) |
| Cisplatin based | 6 (26.1) |
| Immunotherapy | 3 (13) |
| Chemotherapy concurrent with prior radiation therapy | |
| Capecitabine | 8 (34.8) |
| Infusional 5-Fluorouracil | 8 (34.8) |
| Gemcitabine | 3 (13) |
| Other | 4 (17.4) |
| CA19-9 at recurrence, U/mL | 201 [1.0-3098.9] |
∗
Regimens are not mutually exclusive.